Regeneron Pharmaceuticals Receives Strong Value Investor Rating

Regeneron Pharmaceuticals Inc shines in a recent analysis. The stock's score of 71% indicates solid fundamentals, although concerns around its P/E and price/book ratios may concern investors.

Date: 11-01-2025

AI Rating: 6

Earnings Per Share (EPS): The report does not provide specific EPS figures, but mentions long-term EPS growth, indicating potential for future earnings improvement.

Revenue Growth: Specific revenue growth figures are not presented in the analysis, yet general sales are marked as a strength. This might suggest stable operations or growth in sales.

Net Income: There is no mention of net income or related metrics, leaving investors without critical insights in this area.

Profit Margins: The report lacks specific insights into profit margins (gross, operating, net), making it impossible to evaluate overall profitability.

Free Cash Flow (FCF): There is no direct reference to free cash flow, which is important for understanding financial flexibility.

Return on Equity (ROE): The report does not include information on ROE, which would have provided insights into management effectiveness.

Overall, the report highlights that Regeneron Pharmaceuticals holds a score of 71% based on the Value Investor model developed by Benjamin Graham. A passing rating in sectors such as debt management and long-term earnings growth is a positive signal to investors. However, the failures in the P/E and price/book ratios raise some red flags, suggesting that the stock might be overvalued compared to its intrinsic value. Hence, while there are strengths, such as solid long-term growth expectations, the failures may temper enthusiasm among potential investors.

Stocks: REGN